Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments

NCT ID: NCT06997549

Last Updated: 2025-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

12000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-15

Study Completion Date

2035-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

this is a retrospective data analysis study that will utilize the already collected data as clinical care and will help understand the utilization and efficacy of various treatment options available for various mental heath conditions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression OCD Anxiety Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients treated with NeuroStar TMS

non-invasive brain stimulation device

Intervention Type DEVICE

Patients treated with Esketamine

nasal spray for treating depression

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TMS spravato

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female reported in database and not an invalid entry
* Age reported and not an invalid entry
* Treatment date in 2011 or later.

Exclusion Criteria

• Incomplete information on treatment parameters
Minimum Eligible Age

5 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Neuronetics

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eleanor Cole, PhD

Role: STUDY_DIRECTOR

Neuronetics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Neuronetics

Malvern, Pennsylvania, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Neha Goyal

Role: CONTACT

7635281599

Eleanor Cole, PhD

Role: CONTACT

415-724-7960

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Eleanor Cole

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11-10002-000

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clinical Study of GH001 in Depression
NCT04698603 COMPLETED PHASE1/PHASE2
Levomilnacipran in Healthy Males
NCT03249311 UNKNOWN PHASE4
Ketamine + Mindfulness for Depression
NCT05168735 COMPLETED PHASE1/PHASE2